VALBIOTIS Authorized to Launch HEART, the Phase II Multi-center Clinical Study With TOTUM-070, for the Reduction of Blood LDL-cholesterol Levels
VALBIOTIS (FR0013254851 – ALVAL / eligible for the PEA/SME, French equity savings plan for the financing of SMEs) (Paris:ALVAL), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces that it has received a positive opinion from the CPP and authorization from the ANSM to launch HEART, a multi-centric Phase II clinical study with TOTUM-070, for the reduction of blood LDL-cholesterol levels, a risk factor for cardiovascular disease.
The main objective of this clinical study is to evaluate the efficacy of a 5g daily dose of TOTUM-070 and to confirm its safety. HEART results will support the application for a proprietary health claim related to the reduction of LDL-cholesterol, a risk factor for cardiovascular disease.
These authorizations make it possible to begin enrolling 120 people with untreated mild to moderate LDL-hypercholesterolemia in the study.
Professor Jean-Marie Bard, PharmD, PhD, Professor and Hospital Practitioner at Nantes University Hospital, scientific advisor for the Phase II clinical study, declared: “The need for an additional, effective and well-tolerated tool in the clinical arsenal to rapidly reduce LDL-cholesterol without waiting for the situation to deteriorate is currently not fully met. TOTUM-070 offers, in this regard, new promise for patients with genuine cardiovascular risk. By acting on LDL-cholesterol, the risk of cardiovascular events is reduced with a positive impact on life expectancy. Improving cardiovascular prognosis is a major public health challenge. As an advisor to the HEART study, I have high hopes for the ability of TOTUM-070 to significantly reduce bad cholesterol levels in the blood.”
Murielle Cazaubiel, member of the Management Board, Head of Development and Medical Affairs at VALBIOTIS, added: “VALBIOTIS is very proud to bring its second active substance, TOTUM-070, to the Phase II clinical stage. The design of the HEART study will provide unequivocal proof of the efficacy of this active substance in hypercholesterolemic patients. This is a key milestone in the development of TOTUM-070 and an exciting prospect for those awaiting alternative solutions. With this second innovative active substance, VALBIOTIS consolidates its breakthrough position in the prevention of metabolic diseases.
We wish to warmly thank all the healthcare professionals involved in this study.”
The Phase II randomized, double-blind, placebo-controlled clinical study will include 120 people with untreated moderate hypercholesterolemia between 130 and 190 mg/dL. Participants will be divided into 2 equivalent arms of 60 people, supplemented for 6 months with TOTUM-070 or placebo. The primary endpoint of the study will be the reduction of blood LDL-cholesterol levels, with several secondary objectives of interest.
Results are expected at the beginning of 2022.
In line with VALBIOTIS' business model, the objective is to conclude a partnership and license agreement for the marketing of TOTUM-070 with a global healthcare player. In February 2020, this model enabled VALBIOTIS to sign a strategic partnership with Nestlé Health Science for the active substance TOTUM-63, aimed at reducing the risk of type 2 diabetes in prediabetic individuals.
TOTUM-070 is an innovative active substance derived from food plant extracts, free from phytosterols and red rice yeast, developed to act on lipid metabolism in hypercholesterolemic subjects.
This exclusive active substance is especially developed for people with mild to moderate LDL-cholesterol levels, up to 190 mg/dL, untreated and associated with a moderate overall cardiovascular risk.
TOTUM-070 benefits from intellectual property backed by patents in the world's main markets: Europe, the United States, Russia, South Africa and national phases in progress in the United Arab Emirates, Brazil, Canada, Japan, China, Australia and Mexico.
The goal of TOTUM-070 clinical development is to obtain a proprietary health claim related to the reduction of blood LDL-cholesterol, a risk factor for cardiovascular disease.
Excess LDL-cholesterol is a widespread cardiovascular risk factor, found in nearly 40% of the world's adult population, according to WHO data.
VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.
VALBIOTIS has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of nutritional health solutions designed to reduce the risk of major metabolic diseases, based on a multi-target approach and made possible by the use of plant-based ingredients.
Its products are intended to be licensed to players in the health world.
VALBIOTIS was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63).
VALBIOTIS is a member of the “BPI Excellence” network and received “Innovative Company“ status awarded by BPI France. Valbiotis has also been awarded “Young Innovative Company” status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). VALBIOTIS is a PEA-SME eligible company.
Find out more about VALBIOTIS: www.valbiotis.com
ISIN code: FR0013254851
Mnemonic code: ALVAL
EnterNext© PEA-SME 150
This press release contains forward-looking statements about VALBIOTIS’ objectives, based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be affected by changes in economic conditions and financial markets, as well as a certain number of risks and uncertainties, including those described in the VALBIOTIS registration document, filed with the French Financial Markets Regulator (AMF) on 31 July 2020 (application number R 120-018). This document is available on the Company’s website (www.valbiotis.com).
This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, VALBIOTIS’ shares or securities in any country.
VALBIOTIS / CORPORATE COMMUNICATION
Carole Rocher / Marc Delaunay
+33 5 46 28 62 58
ACTIFIN / FINANCIAL COMMUNICATION
+33 1 56 88 11 14
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hyosung TNS Invites Customers to ‘Be Inspired’ With New Campaign25.2.2021 17:00:00 CET | Press release
Hyosung TNS, the world-leading ATM manufacturer, has begun a global initiative to reinvent its user experience through the implementation of a branding refresh titled “Be Inspired.” The campaign draws upon the impressive technological history of the industry innovator to lead clients through a journey to experience solutions-driven communication. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210225005240/en/ Hyosung TNS' technologically impressive, new 140-page website has been designed to unify Hysoung's leadership in the financial institution and retail industries and consolidate all of its previous, regional websites into one global website, including a multi-language interface and an intuitive, interactive product catalog. (Photo: Business Wire) The “Be Inspired” initiative employs “plain language and interaction” that show how Hyosung is inspired by its customers to create new business solutions – and how those solutio
MyHeritage lanserer en banebrytende funksjon for å animere ansiktene i stillbilder25.2.2021 16:49:00 CET | Pressemelding
MyHeritage er verdens største globale tjenesten for å oppdage din fortid og styrke din fremtid. I dag annonserer selskapet Deep Nostalgia™, det en ny fotofunksjon som animerer ansikter i stillbilder. Deep Nostalgia™ gir slektshistorie et nytt perspektiv ved å produsere realistiske skildringer av hvordan mennesker kunne ha beveget seg og sett ut, hvis de hadde blitt videofilmet. MyHeritage er det eneste selskapet som tilbyr en komplett pakke med funksjoner for å fargelegge, gjenopprette, forbedre og nå animere historiske bilder. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20210225005805/no/ Introducing Deep Nostalgia™ (Photo: Business Wire) Denne teknologien som animerer ansikter i bilder ble lisensiert av MyHeritage fra D-ID, som er et selskap som har spesialisert seg på videorekonstruksjon ved hjelp av dyp læringteknologi. Deep Nostalgia™ bruker flere forhåndsdefinerte beveglsesvideoer som er utarbeidet av MyHeritage
CMT’s New Report Confirms Increasing Appetite for Connected Insurance in Europe25.2.2021 16:25:00 CET | Press release
A large shift in driving habits due to the COVID-19 pandemic has changed how people think about motor insurance across Europe, according to a new study by Cambridge Mobile Telematics (CMT), the world’s leading mobile telematics and analytics provider. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210225005773/en/ (Graphic: Business Wire) Based on the surveys of 4,000 drivers in France, Germany, Italy and the U.K., the new report shows shifting attitudes towards quoting channels, claims services, pricing models and value-added services, broken down and analysed by location, age and driving behaviour. The two surveys - taken in January 2020, before the pandemic, and then nine months later in September 2020 - reveal up to 81 percent of the drivers in Europe have changed how they drive because of COVID-19. Now 65 percent are interested in connected insurance, a 32% jump in nine months. The pandemic has modified commuting patter
Alpega Group Showed Impressive Results In 202025.2.2021 16:00:00 CET | Press release
Alpega Group, a leading provider of end-to-end transportation and logistics management software, has positioned itself to meet logistics challenges with impressive results in 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210225005665/en/ Alpega Group, a leading provider of end-to-end transportation and logistics management software, has positioned itself to meet logistics challenges with impressive results in 2020. (Photo: Alpega Group) Alpega’s business units had an outstanding performance last year. On one hand, their freight exchanges’ customer acquisitions strongly grew by 20% compared to the previous year and existing clients had a higher renewal rate. On the other hand Alpega TMS added 83 new customers and had a tremendous increase in usage of their smart booking solution. Alpega’s CEO, Todd DeLaughter, commented on these results: “I’m very excited with Alpega’s excellent performance proving the value of our sol
MyHeritage Releases Groundbreaking Feature to Animate the Faces in Still Photos25.2.2021 15:54:00 CET | Press release
MyHeritage, the leading global service for discovering your past and empowering your future, announced today the release of Deep Nostalgia™, a new feature that animates the faces in still photos. Deep Nostalgia™ gives family history a fresh new perspective by producing a realistic depiction of how a person could have moved and looked if they were captured on video. MyHeritage is the only company to offer a complete suite of features for colorizing, restoring, enhancing, and now animating historical photos. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210225005747/en/ Introducing Deep Nostalgia™ (Photo: Business Wire) The technology for animating the faces in photos was licensed by MyHeritage from D-ID, a company that specializes in video reenactment using deep learning. Deep Nostalgia™ uses several pre-recorded driver videos prepared by MyHeritage, which direct the movements in the animation and consist of sequences of rea
Andersen Global Enhances Caribbean Platform with Baptiste & Co. Law Firm25.2.2021 15:30:00 CET | Press release
Further strengthening its Caribbean platform and adding additional coverage in the southern edge of the region, Andersen Global expands into St. Vincent and the Grenadines with collaborating firm Baptiste & Co. Law Firm. Established in 1986, Baptiste & Co. Law Firm, was founded by Managing Partner René M. Baptiste, who possesses more than 40 years of experience. In addition to founding the firm, René’s accomplishments include admission to the Bar in St. Vincent and the Grenadines, Antigua and Barbuda, Saint Kitts and Nevis; published articles in the International Finance journal; two terms of service as an elected member of Parliament and Cabinet Minister in St. Vincent and the Grenadines; and the role of Speaker of the Organization of Eastern Caribbean States’ Assembly. Additionally, she possesses well over 50 years of public service, which has resulted in recognition from Her Majesty Queen Elizabeth II in the form of elevation to Commander of Saint Michael and Saint George (CMG) for
C3 AI Awarded Robust Omnibus U.S. Patent for End-to-End Enterprise AI Platform25.2.2021 15:00:00 CET | Press release
C3 AI today announced that it was awarded a broad-ranging omnibus patent for the company’s end-to-end enterprise AI solution, C3 AI® Suite, further solidifying the company’s position as a leading enterprise AI software provider for accelerating digital transformation, as well as strengthening C3 AI’s intellectual property and competitive advantage. The newly issued U.S. patent (No.10,817,530) was granted for “systems, methods, and devices for an enterprise AI application development platform.” The patent encompasses not only advanced data processing and AI application development, but also the extensive array of techniques necessary to build an end-to-end enterprise AI platform, including C3 AI’s unique model-driven architecture. “This patent is the most significant and substantial we have been awarded to date,” said Thomas M. Siebel, CEO of C3 AI. "When we filed years ago, no one else conceived of a comprehensive, end-to-end solution with a model-driven architecture that accelerates t